

KISUNLA ORDERS (DONANEMAB)

PATIENT INFORMATION		PRESCRIBER INFORMATION	
Patient Name: _____		Prescriber Name: _____	
Address: _____		NPI: _____	
City, State, Zip: _____		Address: _____	
Cell: _____	Email: _____	City, State, Zip: _____	
Height _____	Weight _____	Last 4 of SSN: _____	DOB: _____
Allergies: _____		Phone: _____ Fax: _____	
		Contact Person: _____	

REFERRAL STATUS	
☐ New Referral	☐ Is this the first Dose? Yes/No
☐ Dose or Frequency Change	☐ If no, date of last infusion
☐ Continuation Order	Line type: ☐ PIV ☐ PICC ☐ Port ☐ Other

DIAGNOSIS	
☐ G30.0 Alzheimer's disease with early onset	Z00.6 Encounter for examination for normal comparison and control in clinical research program
☐ G30.1 Alzheimer's disease late onset	☐ F02.80 Dementia without behavioral disturbance
☐ G30.8 Other Alzheimer's disease	☐ F02.81 Dementia with behavioral disturbance
☐ G30.9 Alzheimer's disease, unspecified	☐ G31.84 Mild Cognitive Impairment due to Alzheimer's Disease

REQUIRED DOCUMENTATION	
- This signed order form by the provider - Patient demographics and insurance information - H&P, labs, tests, and progress notes supporting diagnosis	☐ Medicare beneficiaries: NCT registry number: _____ ☐ Date of brain MRI negative for ARIA: _____ ☐ Documentation of amyloid beta pathology by PET scan, CSF sample, or Plasma sample
SUBSEQUENT BRAIN MRI AND WRITTEN APPROVAL FROM ORDERING PROVIDER MUST BE OBTAINED PRIOR TO INFUSING 2 ND , 3 RD , 4 TH , AND 7 TH INFUSION.	

PRESCRIBING INFORMATION			
Medication	Dose/Strength	Directions	Quantity
☐ Donanemab-azbt (Kisunla)	350 mg/20 mL	☐ New Start Infuse IV in 0.9% NS for final concentration of 4mg/mL to 10mg/mL over 30 minutes every 4 weeks as follows - Infusion 1, Infuse 350 mg x 1 dose - Infusion 2, Infuse 700 mg x 1 dose (hold for MRI results) - Infusion 3, Infuse 1050 mg x 1 dose (hold for MRI results)	6 vials
		☐ Maintenance Infusions 4-18, Infuse 1400 mg IV in 0.9% NS for final concentration of 4mg/mL to 10mg/mL over 30 minutes every 4 weeks (hold infusions 4 and 7 for MRI results)	4 vials Refill x 11
Observation		Observe patient for a minimum of 30 minutes post infusion	
☐ Acetaminophen	650 mg	650 mg po prior to infusion	
☐ Diphenhydramine	25 mg	25 mg po prior to infusion	
For PIV flush 3-10 mL 0.9% NS before and after For PICC/Midline flush 10 mL 0.9% NS before/after, then 3 mL Heparin 10 units/mL final flush For Port flush 10 mL 0.9% NS before/after, then 5 mL Heparin 100 units/mL final flush Using 50 mL 0.9% NS bag flush residual priming volume post infusion			

RN to manage VAD per company protocol and administer ordered therapy per manufacturer guideline

RN to access/start and deaccess/discontinue VAD as appropriate for therapy administration

RN to flush and lock VAD/CVAD per company protocol

Other: _____

EMERGENCY MEDICATION

Administer the following medications as needed for infusion-related reactions per company protocol:

Adults (>40 kg): Diphenhydramine 25–50 mg PO or IV slow push (2–5 min); Acetaminophen 325–650 mg PO; Methylprednisolone 125 mg IV slow push (≥5 min); Epinephrine 0.3 mg IM/SQ, may repeat x1; 0.9% NS 500 mL IV over 30–60 min, may repeat x1 for hypotension.

Oxygen (AIC/AIS only): 1–6 L/min via NC or face mask; titrate to maintain SpO₂ 95–100%.

Prescriber Signature X: _____

Product Substitution Permitted: _____ Date: _____

X: _____

Dispense as Written: _____ Date: _____